$0.01
(Market cap
$4 Mln
Revenue (TTM)
$108 Mln
P/E Ratio
--
P/B Ratio
34.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.7 %
-
ROCE
-- %
-
Industry P/E
44.46
-
EV/EBITDA
20.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.4
-
Face value
--
-
Shares outstanding
30,388,635
10 Years Aggregate
CFO
$66.43 Mln
EBITDA
$103.08 Mln
Net Profit
$70.33 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zynex (ZYXI)
| -36.3 | 7.5 | -86.1 | -98.8 | -81.0 | -65.0 | -11.7 |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Zynex (ZYXI)
| -98.3 | -26.3 | -21.7 | 70.9 | -25.9 | 71.0 | 167.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Zynex (ZYXI)
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a... dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. On December 15, 2025, Zynex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. Read more
-
Founder, President, CEO & Chairman
Mr. Thomas Sandgaard
-
Founder, President, CEO & Chairman
Mr. Thomas Sandgaard
-
Headquarters
Englewood, CO
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Zynex (ZYXI)
What is the current share price of Zynex Inc (ZYXI) Today?
The share price of Zynex Inc (ZYXI) is $0.09 (NASDAQ) as of 24-Feb-2026 09:30 EDT. Zynex Inc (ZYXI) has given a return of -81.05% in the last 3 years.
What is the current PB & PE ratio of Zynex Inc (ZYXI)?
Since, TTM earnings of Zynex Inc (ZYXI) is negative, P/E ratio is not available.
The P/B ratio of Zynex Inc (ZYXI) is 34.84 times as on 24-Feb-2026, a 819 premium to its peers’ median range of 3.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
86.41 |
7.25 |
2023 |
38.06 |
8.03 |
2022 |
30.97 |
7.96 |
2021 |
22.95 |
5.31 |
2020 |
58.14 |
9.28 |
What is the 52 Week High and Low of Zynex Inc (ZYXI)?
The 52-week high and low of Zynex Inc (ZYXI) are Rs 7.58 and Rs 0.03 as of 01-Sep-2026.
What is the market cap of Zynex Inc (ZYXI)?
Zynex Inc (ZYXI) has a market capitalisation of $ 4 Mln as on 24-Feb-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Zynex Inc (ZYXI)?
Before investing in Zynex Inc (ZYXI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.